A recent study [30] found that in patients with biochemical recurrence and in the absence of radiological evidence of metastatic disease on CT or bone scan [68Ga]Ga-PSMA PET/CT may lead to a change in management for up to 96% of patients. Here, FOLH1 is linked to metastatic neoplasm.